Bladder cancer market to expand at 12.5% CAGR

The bladder cancer space across the seven major markets (7MM) of the USA, France, Germany, Italy, Spain, the UK and Japan, is set to more than triple in size from $360 million in 2015 to around $1.17 billion by 2025, at a compound annual growth rate of 12.5%.

According to research and consulting firm GlobalData’s latest report, this impressive growth will be driven by the increased incorporation of immunotherapies into treatment algorithms, the launch of new combination therapies, increased incident cases of bladder cancer across the 7MM, and the introduction of the pipeline agents CG-0070 from Cold Genesys, vicinium from Eleven Biotherapeutics (Nasdaq: EBIO) and Cyramza (ramucirumab) from Eli Lilly (NYSE: LLY).

Historically the bladder cancer market has been highly generic, with Bacillus Calmette-Guerin (BCG) and chemotherapies dominating the landscape. However, with the launch of Tecentriq (atezolizumab) from Roche (ROG: SIX) and the subsequent launch of other programmed cell death protein 1 (PD-1) modulators, bladder cancer treatment algorithms are expected to change during the forecast period.